Cargando…

Specific Increase in MDR1 Mediated Drug-Efflux in Human Brain Endothelial Cells following Co-Exposure to HIV-1 and Saquinavir

Persistence of HIV-1 reservoirs within the Central Nervous System (CNS) remains a significant challenge to the efficacy of potent anti-HIV-1 drugs. The primary human Brain Microvascular Endothelial Cells (HBMVEC) constitutes the Blood Brain Barrier (BBB) which interferes with anti-HIV drug delivery...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roy, Upal, Bulot, Christine, Honer zu Bentrup, Kerstin, Mondal, Debasis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3789726/ https://www.ncbi.nlm.nih.gov/pubmed/24098380 http://dx.doi.org/10.1371/journal.pone.0075374

Ejemplares similares

Mesenchymal stem cell derived hematopoietic cells are permissive to HIV-1 infection
por: Nazari-Shafti, Timo Z, et al.
Publicado: (2011)

Saquinavir: From HIV to COVID-19 and Cancer Treatment
por: Pereira, Mariana, et al.
Publicado: (2022)

Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells
por: Dupuis, Maria Luisa, et al.
Publicado: (2013)

Safety and Efficacy in HIV-1-Infected Patients Treated with Ritonavir-Boosted Saquinavir Mesylate
por: Knechten, Heribert, et al.
Publicado: (2010)

Role of MRP transporters in regulating antimicrobial drug inefficacy and oxidative stress-induced pathogenesis during HIV-1 and TB infections
por: Roy, Upal, et al.
Publicado: (2015)

Immunospecific Responses to Bacterial Elongation Factor Tu during Burkholderia Infection and Immunization
por: Nieves, Wildaliz, et al.
Publicado: (2010)

New-Onset Saquinavir-Induced Diabetes
por: van Zoelen, Marieke A.D., et al.
Publicado: (2013)

Microglial activation decreases retention of the protease inhibitor saquinavir: implications for HIV treatment
por: Dallas, Shannon, et al.
Publicado: (2013)

Tratamiento con saquinavir + zalcitabina + zidovudina vs saquinavir + lamivudina + zidovudina en pacientes con SIDA sin tratamiento previo
por: Jaimes Martínez, Marcos
Publicado: (2000)

Global transcript structure resolution of high gene density genomes through multi-platform data integration
por: O'Grady, Tina, et al.
Publicado: (2016)

The Membrane-Active Phytopeptide Cycloviolacin O2 Simultaneously Targets HIV-1-infected Cells and Infectious Viral Particles to Potentiate the Efficacy of Antiretroviral Drugs
por: Gerlach, Samantha L., et al.
Publicado: (2019)

Understanding Drug Resistance of Wild-Type and L38HL Insertion Mutant of HIV-1 C Protease to Saquinavir
por: Venkatachalam, Sankaran, et al.
Publicado: (2023)

Evaluation of novel Saquinavir analogs for resistance mutation compatibility and potential as an HIV-Protease inhibitor drug
por: Jayaswal, Amit, et al.
Publicado: (2014)

The HIV-protease inhibitor saquinavir reduces proliferation, invasion and clonogenicity in cervical cancer cell lines
por: Bandiera, Elisabetta, et al.
Publicado: (2016)

Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis
por: Tommasi, Chiara, et al.
Publicado: (2011)

Unexpected Hepatotoxicity of Rifampin and Saquinavir/Ritonavir in Healthy Male Volunteers
por: Schmitt, Christophe, et al.
Publicado: (2009)

Potential Hepatotoxicity of Efavirenz and Saquinavir/Ritonavir Coadministration in Healthy Volunteers
por: Jamois, Candice, et al.
Publicado: (2009)

A Case of Nephrotic Syndrome, Showing Evidence of Response to Saquinavir
por: Walters, Giles, et al.
Publicado: (2015)

Saquinavir plus methylprednisolone ameliorates experimental acute lung injury
por: Zhang, Guanghua, et al.
Publicado: (2018)

Saquinavir-Piperine Eutectic Mixture: Preparation, Characterization, and Dissolution Profile
por: Fandaruff, Cinira, et al.
Publicado: (2023)

Short-Term Administration of HIV Protease Inhibitor Saquinavir Improves Skull Bone Healing with Enhanced Osteoclastogenesis
por: Liu, Haixia, et al.
Publicado: (2022)

The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?
por: Wiesmann, Frank, et al.
Publicado: (2011)

A Simple Method for Assessment of MDR Bacteria for Over-Expressed Efflux Pumps
por: Martins, Marta, et al.
Publicado: (2013)

The Transcription Factor Mrr1p Controls Expression of the MDR1 Efflux Pump and Mediates Multidrug Resistance in Candida albicans
por: Morschhäuser, Joachim, et al.
Publicado: (2007)

Enhancement of saquinavir absorption and accumulation through the formation of solid drug nanoparticles
por: Kigen, Gabriel, et al.
Publicado: (2018)

Repurposing Saquinavir for Host-Directed Therapy to Control Mycobacterium Tuberculosis Infection
por: Pires, David, et al.
Publicado: (2021)

Synthesis of biogenic gold nano conjugate for increased efficacy and sustained drug release profile of saquinavir
por: Kesarkar, Rohan, et al.
Publicado: (2014)

Differential Gene Expression of Efflux Pumps and Porins in Clinical Isolates of MDR Acinetobacter baumannii
por: AlQumaizi, Khalid I., et al.
Publicado: (2022)

Role of the MDR Efflux Pump AcrAB in Epithelial Cell Invasion by Shigella flexneri
por: Coluccia, Marco, et al.
Publicado: (2023)

Extracts from Argentinian native plants reverse fluconazole resistance in Candida species by inhibiting the efflux transporters Mdr1 and Cdr1
por: Gil, Florimar, et al.
Publicado: (2022)

Photodynamic Inactivation Effectively Eradicates Candida auris Biofilm despite Its Interference with the Upregulation of CDR1 and MDR1 Efflux Genes
por: Štefánek, Matúš, et al.
Publicado: (2022)

A Novel MFS-MDR Transporter, MdrP, Employs D223 as a Key Determinant in the Na(+) Translocation Coupled to Norfloxacin Efflux
por: Zhang, Rui, et al.
Publicado: (2020)

Novel intravaginal nanomedicine for the targeted delivery of saquinavir to CD4(+) immune cells
por: Yang, Sidi, et al.
Publicado: (2013)

Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients
por: Stephan, C, et al.
Publicado: (2010)

Efficacy, Safety and Pharmacokinetics of Once-Daily Saquinavir Soft-Gelatin Capsule/Ritonavir in Antiretroviral-Naive, HIV-Infected Patients
por: Julio, Montaner SG, et al.
Publicado: (2006)

MDR1 in immunity: friend or foe?
por: Bossennec, Marion, et al.
Publicado: (2018)

Mathematical Modelling Highlights the Potential for Genetic Manipulation as an Adjuvant to Counter Efflux-Mediated MDR in Salmonella
por: Youlden, George, et al.
Publicado: (2022)

Drug Resistance Mechanism of M46I-Mutation-Induced Saquinavir Resistance in HIV-1 Protease Using Molecular Dynamics Simulation and Binding Energy Calculation
por: Rana, Nilottam, et al.
Publicado: (2022)

Inhibition of Streptococcus mutans biofilms with bacterial-derived outer membrane vesicles
por: Wang, Yihui, et al.
Publicado: (2021)

Repurposing Alone and in Combination of the Antiviral Saquinavir with 5-Fluorouracil in Prostate and Lung Cancer Cells
por: Pereira, Mariana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k2bsribe00c0kpe99i0jg588gk